Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

James M. Foran, Steven Z. Pavletic, Brent R. Logan, Manza A. Agovi-Johnson, Waleska S. Pérez, Brian J. Bolwell, Martin Bornhäuser, Christopher N. Bredeson, Mitchell S. Cairo, Bruce M. Camitta, Edward A. Copelan, Jason Dehn, Robert P. Gale, Biju George, Vikas Gupta, Gregory A. Hale, Hillard M. Lazarus, Mark R. Litzow, Dipnarine Maharaj, David I. MarksRodrigo Martino, Richard T. Maziarz, Jacob M. Rowe, Philip A. Rowlings, Bipin N. Savani, Mary Lynn Savoie, Jeffrey Szer, Edmund K. Waller, Peter H. Wiernik, Daniel J. Weisdorf

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P <.001), with Karnofsky Performance Status score ≥90% (HR, 0.62; 95% CI, 0.47-0.82: P= .001) and in cytomegalovirus-negative recipients (HR, 0.64; 95% CI, 0.44-0.94; P= .022). A longer interval (>18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P <.001) and improved leukemia-free survival (HR, 0.53; 95% CI, 0.34-0.84; P= .006). URD allo-HCT after auto-HCT relapse resulted in 20% long-term leukemia-free survival, with the best results seen in patients with a longer interval to secondary URD transplantation, with a Karnofsky Performance Status score ≥90%, in complete remission, and using an RIC regimen. Further efforts to reduce treatment-related mortaility and relapse are still needed.

Original languageEnglish (US)
Pages (from-to)1102-1108
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number7
DOIs
StatePublished - Jul 2013

Bibliographical note

Funding Information:
Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute , and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 5U01HL069294 from the National Cancer Institute and the National Heart, Lung and Blood Institute ; Contract HHSH234200637015C with the Health Resources and Services Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Amgen, Angioblast , anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene, CellGenix, Children’s Leukemia Research Association, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia and Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA , Miltenyi Biotec, National Marrow Donor Program, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Therakos, and Wellpoint . The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

Keywords

  • Acute myelogenous leukemia
  • Allogeneic
  • Autologous
  • Transplantation
  • Unrelated donor

Fingerprint Dive into the research topics of 'Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research'. Together they form a unique fingerprint.

Cite this